Humphrey David Carl 4
4 · Ensysce Biosciences, Inc. · Filed Feb 4, 2022
Insider Transaction Report
Form 4
Humphrey David Carl
Chief Financial Officer
Transactions
- Award
Stock Option
2022-02-04+275,000→ 275,000 totalExercise: $3.13Exp: 2032-02-04→ Common Stock (275,000 underlying)
Footnotes (1)
- [F1]On February 4, 2022, Mr. Humphrey was granted an option (the "Stock Option") to purchase 275,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 11, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter.